Communique from annual general meeting in prostatype genomics AB (publ)
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
The annual general meeting in Prostatype Genomics AB (publ), corp. reg. no 556726-0285 (the “Company”) was held on 23 May 2024. Below is a summary of the decisions that were made. All decisions were made unanimously.
Annual report and results
The annual general meeting adopted the income statement and the balance sheet for the financial year 2023 and resolved, in accordance with the board of directors’ proposal, that the result according to the approved income statement should be transferred to a new account. No dividends are to be paid.
Discharge from liability
The general meeting granted the board of directors as well as the managing director discharge from liability for the management of the Company’s business for the financial year 2023.
Remuneration to the board of directors and the auditor
The annual general meeting resolved that the chairman shall receive remuneration with SEK 160,000 and that every other board member shall receive remuneration with SEK 80,000, unless the member in question is not prevented from receiving such remuneration due to the applicable guidelines of the member’s employer.
The annual general meeting resolved that the auditor shall receive remuneration according to approved invoice.
Election of board of directors and auditor
The annual general meeting resolved that the board of directors shall consist of six (6) directors without any deputy directors.
The general meeting resolved, for the time until the end of the next annual general meeting, to re-elect Anders Lundberg, Michael Häggman, Mattias Prage, Håkan Englund and Jörgen Dahlström as members of the board of directors. Further, Johan Waldhe was elected as new member of the board. Anders Lundberg was elected as the chairman of the board of directors.
It was resolved to re-elect Grant Thornton Sweden AB as auditor for the time until the end of the next annual general meeting.
Nomination committee for the annual general meeting 2025
The annual general meeting resolved that the Company, in advance of the annual general meeting in 2025, shall establish a nomination committee. It was resolved that the members of the nomination committee shall be appointed by instruction from the chairman of the board of directors to the three largest shareholders in the Company on 30 September 2024 to appoint a representative each that, together with the chairman of the board of directors, shall constitute the nomination committee.
Authorization to the board of directors to resolve on new issues
The annual general meeting authorized the board of directors to, on one or several occasions for the time until the next annual general meeting, resolve on issues of shares, warrants and/or convertible loans (or combinations thereof, so-called units). If the board exercises the authorization, this may also be done with a deviation from the shareholders' preferential rights and/or with provisions on non-cash or set-off. An issue in accordance with the authorization shall be made at fair market value.
Amendment of the articles of association
The annual general meeting resolved to amend the articles of association in accordance with the following:
Ӥ 3. Business
The company objective is to, directly and indirectly, engage in research, development, and sales of medical devices and pharmaceuticals, own and manage stock and other securities, as well as activities related thereto.”